Point-of-care multiplex PCR promises short turnaround times for microbial testing in hospital-acquired pneumonia – an observational pilot study in critical ill patients by Nils Kunze et al.
Kunze et al. Annals of Clinical Microbiology and Antimicrobials  (2015) 14:33 
DOI 10.1186/s12941-015-0091-3RESEARCH Open AccessPoint-of-care multiplex PCR promises short
turnaround times for microbial testing in
hospital-acquired pneumonia – an
observational pilot study in critical
ill patients
Nils Kunze1*, Onnen Moerer1, Nicolas Steinmetz1, Marco H. Schulze2, Michael Quintel1 and Thorsten Perl1Abstract
Background: The early beginning of an adequate antibiotic therapy is crucial in hospital-acquired pneumonia
(HAP), but depends on the results of conventional microbiological diagnostics (cMD). It was the aim of this study to
evaluate the performance and turnaround times of a new point-of-care multiplex polymerase chain reaction (mPCR)
system for rapid identification of pathogens and antibiotic resistance markers. We assessed the applicability of the
system under real-life conditions in critical ill patients with HAP.
Methods: We enrolled forty critical ill patients with clinical signs for HAP into an observational study. Two samples
of respiratory secretions were collected during one course of aspiration and cMD and mPCR testing (Unyvero, Curetis
AG, Holzgerlingen, Germany) were performed immediately. The mPCR device was operated as a point-of-care system
at the intensive care unit. We compared turnaround times, results of pathogen identification and results of antibiotic
resistance testing of both methods.
Results: Mean turnaround times (min-max) were 6.5 h (4.7–18.3 h) for multiplex PCR and 71 h (37.2–217.8 h) for
conventional microbiology (final cMD results, incomplete results neglected). 60 % (n = 24) of the mPCR tests were
completely valid. Complete test failure occurred in 10 % (n = 4) and partial test failure occurred in 30 % (n = 12). We
found concordant results in 45 % (n = 18) and non-concordant results in 45 % (n = 18) of all patients. 55 % (n = 16) of
the results were concordant in patients with a clinical pulmonary infection score (CPIS) > 5 (n = 29). Concordant results
included three cases of multidrug resistant bacteria. MPCR frequently detected antibiotic resistance markers that were
not found by cMD.
Conclusions: Unyvero allowed point-of-care microbial testing with short turnaround times. The performance of the
system was poor. However, an improved system with a more reliable performance and an extended microbial panel
could be a useful addition to cMD in intensive care medicine.
Trial registration: ClinicalTrials.gov NCT01858974 (registered 16 May 2013)
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Hospital-acquired pneumonia (HAP) is the second most
common nosocomial infection in the intensive care unit
(ICU) and accounts for about 25 % of all infections [1].
Patients receiving mechanical ventilation are at particu-
lar risk for developing lower respiratory tract infections.
Mortality, morbidity and therapy costs are increased in
patients suffering from HAP [1]. Early and adequate
antibiotic therapy has major impact on the outcome of
these patients [2].
The rapid start of an adequate antimicrobial therapy
still is foiled by a lack of fast and reliable methods for
the identification of the etiologic pathogen. Conventional
microbiological diagnostic methods, such as culturing of
lower respiratory tract secretions, enable reliable identi-
fication of pathogens and their antibiotic resistances.
However, with turnaround times between 48 and 72 h
these methods are slow and intensive care practitioners
are forced to start broad-spectrum antibiotic therapy based
on the patient’s risk profile and knowledge of the local pat-
terns of microbes and antibiotic resistance [3]. Besides the
risk for an ineffective therapy, such treatment regimen can
contribute to the induction of drug-resistances.
A fast and reliable method for the identification of mi-
crobes could help to reduce the time to initiate an opti-
mal antibiotic therapy, improve patient’s outcome and
lower the risk for the induction of drug-resistances.
Genomic, proteomic and metabolomic methods have
been proposed for that purpose, but are currently not
routinely used [4–6].
With the Unyvero multiplex PCR device (Curetis AG,
Holzgerlingen, Germany) a new point-of-care application
for the identification of pathogens and their drug resis-
tances directly from respiratory secretions recently was
made available.
It was the purpose of this study to evaluate the point-
of-care performance of Unyvero in the setting of HAP in
the ICU. Therefore we collected specimen of respiratory
secretions from ICU patients with clinical diagnosed
HAP and compared the results and turnaround times
with the performance of conventional microbiological
diagnostics (cMD).Methods
This observational study was approved by the ethical
committee of the Faculty of Medicine of the Univer-
sity of Göttingen (1/7/06, amendment 3) and informed
consent was obtained from patients after recovery
from acute illness. According to the approval of the
ethical committee we did not exclude patients who
did not recover and died during their ICU stay. The
study was registered at ClinicalTrial.gov (www.clini-
caltrials.gov; NCT01858974).Between April 2013 and January 2014, adult (>18 years)
patients from two ICUs of the University Medical Centre
of Göttingen were prospectively enrolled.
Inclusion criteria were: Onset of clinical symptoms of
pneumonia > 48 h after hospital-admission and sampling
of respiratory secretion for microbiological diagnostics
under the suspect of pneumonia. The adapted clinical
pulmonary infection score (CPIS) was calculated for
each patient [7].
Exclusion criteria were: Enrollment for an interven-
tional clinical trial, and suspect for an infection with a
pathogen of risk class ≥ 3 according to German law (e.g.
Mycobacterium tuberculosis).
After study inclusion, two samples of respiratory secre-
tion were collected during one course of direct endo-
tracheal aspiration (ventilated patients) or nasopharyngeal
tracheal aspiration (non-ventilated patients). One specimen
was sent to the Institute for Medical Microbiology for
cMD. Turnaround times for cMD were calculated for the
complete final results (including antibiotic resistance test-
ing). We neglected early non-written and/or incomplete
cMD results, as we were not able to raise reliable turn-
around times for those.
The second specimen was used for Unyvero (Curetis AG,
Holzgerlingen, Germany) mPCR testing at the ICU and
processed according to the manufacturer’s manual: 180 μl
of the aspirate were loaded into a sample tube for pathogen
lysis. After 30 min in the Unyvero L4 Lysator the sample
tube and the so called master mix tube (containing the ne-
cessary reactants) were loaded into the self-containing cart-
ridge (Unyvero P50 Pneumonia Cartridge, Curetis AG,
Holzgerlingen, Germany) and transferred into the Unyvero
A50 Analyzer for further processing, including DNA ampli-
fication and detection of the amplified sequences. Detailed
information on the working principle of the system can be
found on the manufacturer’s website (www.curetis.com).
The mPCR system was operated at the ICU. The intensive
care physician on duty managed the samples and per-
formed the mPCR tests. For both methods, mPCR and
cMD, turnaround times were defined as the time intervals
between sampling and the availability of the final and vali-
dated results.
Table 1 shows the pathogens (16 bacteria, 1 fungus)
and Table 2 shows the 18 resistance markers detected by
Unyvero. The ICU physician on duty performed mPCR
testing during everyday routine. All personnel performing
mPCR tests for the study was instructed in the use of the
mPCR device.
Descriptive statistical analyses were performed using stat-
istical software (Statistica 10, StatSoft Inc., Tulsa, USA).
Results
Overall, 62 patients were eligible for the study, of whom
22 were excluded due to missing consent, inaccurate
Table 1 Pathogens detected by the mPCR device (according to
the manufacturer)
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tients were enrolled and analyzed according to the study
protocol. Table 3 shows the characteristics of the study
patients.
The mean turnaround time for cMD was 71 h (min-
max: 37.2–217.8 h). The mean turnaround time for
mPCR was 6.5 h (min-max: 4.7–18.3 h).Table 2 Resistance markers detected by the mPCR device (accordin




ermA Macrolides / Lincosamides
ermB Macrolides / Lincosamides
ermC Macrolide / Lincosamides
tem Penicillins, 3rd Gen. Cephalosporins
shv Penicillins, 3rd Gen. Cephalosporin
ctx-M Penicillins, 3rd Gen. Cephalosporins
dha 3rd Gen. Cephalosporins








a pathogen/group of pathogens in which the resistance marker gene is found (accomPCR provided valid results for one or more areas of
the test panel in 36 patients (90 %). Complete test failure
occurred in four patients (10 %). Apart from complete
failure, one or more area of the test panel failed in
twelve patients (30 %). We considered these to be partial
test failures. CMD provided valid results in all 40 pa-
tients (100 %).
In 18 patients (45 %) the results of mPCR were con-
cordant to the results of cMD. Out of these cases, six
patients were concordant positive (15 %) and twelve
were concordant negative (30 %). Non-concordant re-
sults were found in 18 patients (45 %). In two patients
(5 %) cMD alone detected a pathogen. In no case only
mPCR detected a pathogen while cMD did not detect
one. A mismatch between both methods was found in
16 patients (40 %). Figure 1 shows the main results of
the study and the distribution of the partly failed mPCR
analyses to each group. Table 4 shows the detailed re-
sults for all 24 cases with at least one positive result in
mPCR or cMD.
In the sub-group of patients with a CPIS > 5 (n = 29)
mPCR provided valid results for one or more areas of
the test panel in 26 cases. Complete test failure occurred
in three patients (10 %). Partial test failure was seen in
nine cases (31 %). In 16 patients (55 %) results of
mPCR and cMD were concordant. These included the
six patients (21 %) in which both tests were concord-
ant positive and ten patients (34 %) were both tests

















Escherichia coli, Pseudomonas aeruginosa
Escherichia coli, Pseudomonas aeruginosa
Pseudomonas aeruginosa
rding to the manufacturer)
Table 3 Characteristics of the study group
Patients (n = 40)
Mean age (range) 72 (20–86)
Female 27.5 % [11]
Ventilated 65 % [26]
Death on ICU 35 % [14]
Mean CPISa (range) 7 (2–10)
CPIS Temperature 0 = 47.5 % [19] 1 = 20 % [8] 2 = 32.5 % [13]
CPIS Leucocytosis 0 = 30 % [12] 1 = 70 % [28] 2 = 20 % [8]
CPIS Tracheal secretion 0 = 0 % [0] 1 = 30 % [12] 2 = 70 % [28]
CPIS Chest X-Ray 0 = 7.5 % [3] 1 = 40 % [16] 2 = 52.5 % [21]
CPIS PaO2/FiO2-Ratio 0 = 17.5 % [7] - 2 = 82.5 % [33]
CPIS > 5 points 72.5 % [29]
a CPIS at the time of study inclusion, before results of cultivation
were available
[ ] Number of patients
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cases where cMD alone detected a pathogen and eight
cases (28 %) with a mismatch between mPCR and
cMD. Figure 2 summarizes the results for the sub-
group with a CPIS > 5.Fig. 1 Results of all study patientsDiscussion
It was the purpose of this study to evaluate the perform-
ance of a new point-of-care multiplex PCR device for
rapid microbial testing in the setting of HAP at the ICU.
Therefore we performed a pilot study in a real-life ICU
environment.
As expected mPCR provided much shorter turnaround
times than cMD. The very long mean turnaround time of
71.2 h for cMD reflects the fact that we solely surveyed
the time from sampling to the complete cMD results in-
cluding antibiotic resistance testing. We did not measure
turnaround times of incomplete cMD results (such as
gram staining results) that are generally available much
earlier, usually within a few hrs after sample taking.
With 6.5 h, the mean turnaround time of mPCR was
very short. According to the manufacturer one test runs
4.5 h, consisting of 0.5 h for sample lysis and 4 h for
amplification. However, the lysated samples needed to
be transferred from the lysator into the amplification de-
vice. Turnaround times for mPCR in the point-of-care
setting therefore depended on (1) how quick after sam-
pling mPCR was started and, after 30 min of lysation, (2)
how quick the sample was transferred into the amplifica-
tion device. Under the real-life circumstances of a busy
Table 4 Detailed results for all cases with at least one positive result in mPCR or cMD
Case no. Results mPCR pathogens Resistances Results cMD pathogens Resistances
Concordant cases [mPCR (+) = cMD (+)]:
1a Escherichia coli ermB, temb, ctx-Mb, sul1b,
gyrA83b, gyrA87b
Escherichia coli (3-MRGN) SAM, TZP, CXM, CTX, CAZ,
GM, CIP, MXF, SXT,
2 Escherichia coli mecA, ermC, mefA, ermB,
gyrA83b, gyrA87b
Escherichia coli none
3 Staphylococcus aureus ermCb, mefA, sul1 Staphylococcus aureus E, CC
4 Staphylococcus aureus ermB, ermCb Staphylococcus aureus (MRSA) P, OX, SAM, CXM, MXF
5 Enterobacter species ebcb Enterobacter cloacae SAM
6 Staphylococcus aureus mecAb, ermB Staphylococcus aureus (MRSA) P, OX, SAM, CXM, MXF
Non-concordant cases [mPCR (−)≠ cMD(+)]:
7a none none Enterobacter aerogenes none
8a none int1 Haemophilus influenzae,
Citrobacter koseri
none, none
Non-concordant cases [mPCR (+) ≠ cMD(+)]:
9a Moraxella catarrhalis ermB Moraxella catarrhalis,
Klebsiella pneumoniae
none, AM
10 Moraxella catarrhalis, Klebsiella
pneumoniae, Acinetobacter baumanii
mecA, ermC, mefA Klebsiella pneumoniae,
Hafnia alvei
AM, SAM, TZP
11 Streptococcus pneumonia, Chlamydia pneumoniae mefAb, ermBb, tem Enterobacter amnigenus,
Escherichia coli,
AM, CXM, none
12 Haemophilus influenzae, Staphylococcus aureus mecAb, ermB, int1 Staphylococcus aureus P
13 Streptococcus pneumoniae ermC, mefAb, ermBb, ctx-M, kpc Pseudomonas aeruginosa
(4-MRGN)
TZP, CTX, MEM, IPM, CIP, SXT
14a Staphylococcus aureus, Moraxella
catarrhalis, Streptococcus pneumoniae,
Acinetobacter baumanii
ermCb, ermBb Staphylococcus aureus,
Streptococcus pyogenes
P, E, CC, TE, SXT, CIP
15 Streptococcus pneumoniae ermBb Streptococcus anginosus CIP
16a Streptococcus pneumoniae ermBb Citrobacter freundii SAM
17 Moraxella catarrhalis, Serratia marcescens none Serratia marcescens SAM, CXM
18 Streptococcus pneumoniae, Klebsiella oxytoca ermC, mefAb, ermBb, sul1 Enterobacter cloacae SAM
19 Klebsiella pneumoniae, Staphylococcus aureus ermCb, mefA, ermB, dha, ebc Enterobacter cloacae SAM, CXM
20a Serratia marcescens, Pseudomonas aeruginosa gyrA83_2, gyrA87_2, parC Serratia marcescens,
Klebsiella oxytoca
SAM, CXM, SAM, TZP, CXM
21a Escherichia coli, Haemophilus influenzae,
Morganella morganii
dha Proteus mirabilis, Escherichia
coli, Morganella morganii
SXT, SAM, SAM, CXM
22 Moraxella catarrhalis, Streptococcus pneumoniae,
Acinetobacter baumanii, Haemophilus influenzae
ermBb none none
23a Haemophilus influenzae mefA, ermB, temb Proteus mirabilis none




SAM, CXM, MXF, AM, CXM
AM Ampicillin, SAM Ampicillin-Sulbactam, CAZ Ceftazidime, CTX Cefotaxime, CXM Cefuroxime, CIP Ciprofloxacin, CC Clindamycin, SXT Cotrimoxazole, E Erythromycin,
GM Gentamicin, IPM Imipenem, MEMMeropenem, MXFMoxifloxacin, OX Oxacillin, P Penicillin G, TZP Piperacillin-Tazobactam, TE Tetracycline
a Partly test failure mPCR
b Resistance marker encoding for a drug resistance with potential clinical relevance for a pathogen, detected by mPCR
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the mPCR tests. In a recently published study the me-
dian “time to result” for the system has been stated with
only 5.2 h [8]. However, for this study Schulte et al. did
not operate the system as a point-of-care system at an
ICU and therefore mPCR test were started only “on thesame day” as cMD was started. Our study, therefore, is
the first that provides reliable turnaround times in an
ICU point-of-care setting.
We found concordant results (cMD =mPCR) in every
second patient. A slightly higher rate of concordant re-
sults was found in patients with a high probability for
Fig. 2 Results in patients with a CPIS > 5
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mPCR) were caused by a mismatch between both methods.
A main reason for non-concordant results might be
the inacceptable high number of partially failed mPCR
tests. Partial test failure occurred when one or more
areas of the test panel failed to produce valid results.
Complete test failure occurred when not a single area of
the panel produced valid results. One might argue that
the complete failed mPCR tests should also be counted
as non-concordant results, which makes the perform-
ance of the device even more disappointing.
mPCR aims to be a point-of-care test in addition to
cMD with the goal to start adequate antibiotic therapy
more early in critical ill patients. However, we do not ex-
pect this technology to substitute the well-established
methods of cMD in recent years. Costs for mPCR testing
therefore will be additional diagnostic costs and need to
be reasonable for intensive care practitioners. Improve-
ment of the methodology of the system for a better tech-
nical performance with less invalid test results would be
a first step in that direction. There is a need for larger
and interventional trials to show sensibility and specifi-
city of the test in a point-of-care setting and to prove
the influence of mPCR diagnostic on the outcome of
pneumonia patients.
Methodological differences may also contribute to the
high rate of non-concordant results in our study: The
exact differentiation of Streptococcus species by genomicmethods for instance is known to be difficult and some
of the many Streptococcus pneumoniae mPCR results
might reflect this problem [9].
Haemophilus influenzae and S. pneumoniae further-
more are susceptible for non-optimal conditions as they
occur during transport for cMD. Aside from that, mPCR
is able to detect pathogens even when only few (not ne-
cessarily vital) individuals are present in a specimen [10].
Therefore, the number of identified organisms might dif-
fer in both methods. Interpretation of the results should
anticipate these and other differences and limitations of
both methods.
In this context it is important to notice that mPCR
does not provide any information on the presence of
residential flora in the investigated specimen. However,
the detection of an indicator for residential flora would
be useful to evaluate the quality of the specimen, espe-
cially when they are taken via nasopharyngeal aspiration
in non-intubated patients.
Furthermore some resident organisms do carry rele-
vant resistance markers that can lead to a relevant mis-
judgment of mPCR results. The resistance marker gene
mecA for example encodes resistance to methicillin and
is found in both Staphylococcus aureus and Staphylococcus
epidermidis. Unfortunately S. aureus alone is part of the
mPCR panel. Therefore it is not possible for the user to
distinguish whether the detection of mecA in a sample re-
flects relevant information on the resistance pattern of an
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contamination by resident organisms such as S. epidermi-
dis (false positive MRSA) [11]. Case no. 12 in Table 4 gives
an example for such a constellation. Therefore we suggest
an extension of the mPCR panel for bacteria representing
residential flora (e.g. S. epidermidis) to allow the user
to distinguish.
In only six cases both methods detected the same bac-
teria. However, we found three multidrug-resistant bac-
teria strains in these patients (see cases 1, 4 and 6 in
Table 4). Patients suffering from an infection caused by
multidrug-resistant microbes have the highest potential to
benefit from rapid and reliable pathogen identification.
Early administration of the adequate antibiotic is known
to have major impact on the prognosis of these patients
[12]. Under this assumption, a short diagnostic turn-
around time could make a life-saving difference.
Our results confirmed that point-of-care mPCR has
the potential to provide microbial testing with significant
shorter turnaround times than conventional methods.
However, 10 % of the mPCR tests in our study did com-
pletely fail. Another 30 % of the mPCR tests partially
failed. In other words only 60 % of the mPCR tests were
valid and therewith the performance of the device was
not acceptable. Schulte et al. recently published a rate of
not more than 65.7 % valid results in their study of 739
mPCR tests [8]. Our results do confirm these findings. A
reliable technical performance is essential for the suc-
cessful introduction a new diagnostic tool into everyday
clinical use. Besides the medical implications of such an
unreliable technical performance, it will be hard for hos-
pitals to legitimate the costs for such a system and for
the mPCR tests.
The results of our study were strongly influenced by
the poor performance of the system. This fact underlines
the pilot character of the study. However, from our point
of view even the results of such a small observational
study can help to assess the value of a new method for a
specialized field of medical practice, such as intensive
care medicine.
Conclusions
The Unyvero mPCR device allowed point-of-care microbial
testing with short turnaround times. Therefore it could be
a useful addition to cMD because it has the potential to
reduce the time to the start of an adequate antibiotic
therapy, especially when multidrug-resistant bacteria cause
pneumonia.
The actual technical performance of the system is poor
and needs to be improved before more research is done
on its influence on patient’s outcome. The panel should
be extended for at least one indicator for residential
flora, which would allow the user to distinguish between
pathogens and residential contamination.Competing interests
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